This article is for informational and educational purposes only and does not constitute medical advice. Selank is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
The Selank peptide (TKPRPGP) is a synthetic heptapeptide anxiolytic peptide derived from the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. The Pro-Gly-Pro C-terminal extension was appended to the tuftsin core to stabilize the active sequence against rapid exopeptidase degradation — the same design principle used in the development of Semax. Selank research centers on its proposed anxiolytic mechanism of action: reported modulation of GABA-A receptor activity and serotonergic neurotransmission, which have been associated with anxiolytic-like effects across multiple rodent behavioral paradigms. An additional dimension of the Selank research literature concerns its immunomodulatory properties, reflecting the known phagocyte-activating activity of the parental tuftsin tetrapeptide analogue peptide, with reported changes in cytokine profiles observed in some human studies. Selank became available for medical use in Russia during the 2000s for anxiety and asthenic conditions. Like Semax, the Selank research literature is concentrated predominantly in Russian-language sources with limited independent replication outside the originating research group, and this represents a material constraint on evaluating the evidence base.
1. Background
1.1 Origin and Development
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Moscow, by Nikolai Myasoedov, Igor Ashmarin, and colleagues, as part of a broader program investigating synthetic analogues of endogenous peptides for therapeutic application in neurological and psychiatric conditions. The peptide was derived from tuftsin (Thr-Lys-Pro-Arg), an endogenous tetrapeptide fragment identified by Najjar and Nishioka in 1970 as a physiological activator of phagocytic immune cells, released by enzymatic cleavage from the Fc region of IgG heavy chains [4].
In addition to its immunostimulatory properties, tuftsin exhibited behavioral effects in rodent models consistent with anxiolytic and stress-modulating activity. However, tuftsin's therapeutic utility was limited by its rapid degradation in vivo by C-terminal exopeptidases. To address this, the Pro-Gly-Pro tripeptide was appended to the C-terminus of the Thr-Lys-Pro-Arg sequence, yielding the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, designated Selank. The proline residues at positions 5 and 7 confer resistance to carboxypeptidase-mediated cleavage, substantially extending the in vivo half-life of the active tetrapeptide core, using the same C-terminal stabilization strategy employed in Semax development. Selank and Semax were developed within the same Russian neuropeptide research program and share the Pro-Gly-Pro stabilization strategy, although their proposed primary mechanisms differ substantially — Semax being centered on BDNF-mediated neurotrophic signaling and Selank on GABAergic and serotonergic anxiolytic pathways.
Selank became available for medical use in Russia during the 2000s, indicated for anxiety and asthenic disorders. It is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any equivalent regulatory body outside of Russia.
1.2 Research Context
The Selank research literature is concentrated in Russian-language journals and originates predominantly from research groups at the Institute of Molecular Genetics and associated institutions within the Russian Academy of Sciences. As with Semax, this geographic and institutional concentration means that much of the primary mechanistic and clinical evidence base is not independently verifiable by English-language researchers without access to the original Russian-language publications and their methodological details.
A limited number of papers from this group have been published in, or translated into, English. Independent replication by research groups outside Russia is substantially limited. The compound's approved status in Russia does not constitute evidence of efficacy or safety by the standards of Western regulatory agencies, whose approval processes differ materially from those applied at the time of Selank's registration. These limitations are addressed in detail in the limitations section and are a necessary framing for all findings described below.
2. Molecular Structure and Stability
Selank is a linear heptapeptide with the following primary sequence:
2.1 Structural Relationship to Tuftsin
Tuftsin (Thr-Lys-Pro-Arg) is an endogenous tetrapeptide derived from the Fc region of immunoglobulin G heavy chains, released at the C-terminus of the γ-globulin molecule through the sequential action of a splenic endocarboxypeptidase and a leukokinin-activating enzyme. In its endogenous context, tuftsin binds to specific receptors on mononuclear phagocytes and granulocytes, stimulating phagocytic activity, chemotaxis, and cytokine release, and is considered a physiological modulator of innate immune function [4].
Selank retains the complete Thr-Lys-Pro-Arg sequence and is therefore hypothesized to preserve some of the biological properties associated with tuftsin, though the extent to which these activities are retained has not been fully characterized. The high basic charge density of the sequence — contributed by the ε-amino group of Lys at position 2 and the guanidinium group of Arg at position 4 — is characteristic of many endogenous neuropeptides that interact with GABAergic and opioid receptor systems, though whether these charged residues directly mediate any receptor interactions in Selank's case has not been established.
2.2 Metabolic Stability and Routes of Administration
Tuftsin itself is subject to rapid degradation by circulating carboxypeptidases and other serum proteases, severely limiting its in vivo half-life. The Pro-Gly-Pro C-terminal extension in Selank confers resistance specifically to carboxypeptidase-mediated cleavage of the Arg at position 4, which is the primary degradation point for the native tuftsin sequence. This extension substantially prolongs the exposure time of the active tetrapeptide core in vivo relative to tuftsin itself.
As with Semax, intranasal delivery is the primary administration route in Russian clinical practice and in most preclinical research, providing direct access to the olfactory epithelium and potential CNS penetration via the olfactory nerve pathway, reducing first-pass systemic degradation. Detailed human pharmacokinetic characterization of Selank — including bioavailability, CNS penetration fraction, tissue distribution, and metabolite profiles — is not available in the peer-reviewed English-language literature. This represents a significant gap in the evidence base.
3. Proposed Mechanisms of Action
The proposed mechanisms of Selank are more heterogeneous than those of Semax, reflecting both its dual tuftsin/anxiolytic heritage and the range of systems implicated in rodent behavioral studies. The most consistently proposed mechanism is modulation of GABAergic and serotonergic inhibitory tone, which together provide a plausible framework for the anxiolytic effects reported in animal models. Immunomodulatory effects inherited from the tuftsin core, and possible interactions with enkephalin-degrading enzymatic systems, represent additional proposed dimensions. These mechanisms are not mutually exclusive and may operate concurrently.
3.1 GABAₐ Receptor Modulation
GABA-A receptor modulation has been proposed as a primary mechanism underlying Selank's anxiolytic effects in animal models. Rodent studies have reported that Selank produces anxiolytic-like behavioral effects across multiple paradigms — including the elevated plus maze, open field test, and conflict paradigms — with a profile that differs qualitatively from classical benzodiazepines. Specifically, anxiolytic doses of Selank have been reported not to produce the sedation, muscle relaxation, or anterograde amnestic effects typically associated with benzodiazepine receptor agonists at comparably effective anxiolytic doses [1].
This behavioral profile is consistent with partial or site-specific modulation of GABAergic inhibitory tone, rather than global potentiation of GABA-A activity across all receptor subunit configurations. The precise molecular mechanism at the receptor level has not been definitively established. Whether Selank acts at the benzodiazepine binding site, at a distinct allosteric site on the GABA-A receptor complex, or through indirect modulation of GABA synthesis or release has not been resolved in the available literature. Receptor binding studies with radiolabeled Selank at defined subunit compositions have not been published in accessible English-language sources.
3.2 Serotonergic and Monoaminergic Neurotransmission
Several rodent studies have examined Selank's effects on monoaminergic neurotransmitter systems. Narkevich and colleagues reported that Selank modulated serotonin (5-HT) and dopamine content and turnover in limbic and striatal brain regions of rats, with effects that were partially dependent on the animal's baseline anxiety level [5]. In higher-anxiety animals, Selank appeared to normalize elevated monoamine turnover, while effects in lower-anxiety animals were less pronounced. This state-dependent profile, if replicable, would be consistent with an anxiolytic mechanism that engages preferentially under conditions of elevated arousal rather than uniformly suppressing monoaminergic activity.
Semenova and colleagues further reported that chronic stress in rats produced depletion of catecholamines in stress-relevant brain regions, and that Selank administration partially attenuated these stress-induced changes [2]. These findings suggest a role for Selank in preserving monoaminergic resilience under sustained aversive conditions. The mechanistic relationship between these serotonergic and catecholaminergic effects and the primary GABAergic anxiolytic pathway — whether sequential, parallel, or dependent on one another — has not been established.
3.3 Enkephalin System Interaction
Some experimental contexts have produced evidence that Selank may interact with the enzymatic systems responsible for leucine-enkephalin degradation, potentially inhibiting the breakdown of endogenous opioid peptides in neural tissue. Endogenous enkephalins modulate anxiety and stress responses through μ- and δ-opioid receptors in limbic structures including the amygdala and periaqueductal gray, and compounds that reduce enkephalin catabolism can produce anxiolytic-like effects in rodent models.
If substantiated, this mechanism would represent a distinctive feature of Selank relative to conventional anxiolytics, suggesting simultaneous engagement of GABAergic, serotonergic, and enkephalinergic inhibitory systems. However, the evidence for this interaction is limited, few independent studies are available, and the functional significance of any enkephalin degradation inhibition at pharmacologically relevant Selank concentrations has not been established. This pathway should be considered a preliminary hypothesis rather than a characterized mechanism.
3.4 Immunomodulatory Effects
Selank incorporates the complete Thr-Lys-Pro-Arg sequence of tuftsin, and is therefore expected to retain some immunostimulatory activity at the cellular level. In addition to its direct phagocyte-activating effects, tuftsin and its analogues have been reported to influence cytokine production in immune cell populations, with downstream effects on inflammatory signaling that may extend to the neuroimmune axis.
Uchakina and colleagues reported changes in cytokine profiles, including alterations in interleukin-6 (IL-6) levels, in patients with anxiety-asthenic disorders treated with Selank, alongside improvements in anxiety symptom measures [3]. Whether the immunomodulatory and anxiolytic activities of Selank are mechanistically linked — for example, through neuroimmune crosstalk, IL-6-mediated modulation of GABAergic or serotonergic neurotransmission, or microglial anti-inflammatory effects — or represent parallel independent activities of the same peptide has not been established. The immunomodulatory dimension is a feature absent from classical anxiolytics such as benzodiazepines, SSRIs, and buspirone.
4. Key Research Findings
| Research Area | Primary Model(s) | Evidence Level | Key Reported Effects |
|---|---|---|---|
| Anxiolytic Effects | Rat elevated plus maze, open field, conflict models | Preclinical — Moderate | Reduced anxiety-like behavior across multiple paradigms; consistent directional effect without pronounced sedation |
| Serotonergic Modulation | Rat limbic and striatal tissue | Preclinical — Moderate | Altered serotonin and dopamine content in stress-relevant brain regions; state-dependent effect magnitude |
| Anxiety Disorders (Human) | Russian clinical studies (anxiety-asthenic) | Human — Limited | Reported reduction in anxiety symptom scores; small trials, methodology details limited in accessible literature |
| Immunomodulation (Human) | Patient cohort, anxiety-asthenic disorders | Human — Limited | Reported changes in cytokine profiles including IL-6; concurrent with reported anxiolytic response |
| Stress Adaptation | Rat chronic stress models | Preclinical — Limited | Attenuation of stress-induced catecholamine depletion; partial normalization of behavioral stress sequelae |
| Enkephalin Metabolism | In vitro / ex vivo enzymatic assays | Preclinical — Limited | Reported inhibition of leucine-enkephalin degradation; limited replication, functional significance unclear |
4.1 Anxiolytic Effects in Animal Models
The most consistently reported and experimentally reproduced finding associated with Selank is an anxiolytic-like effect in rodent behavioral models. Kozlovskii and Kozlovskaia reported that Selank produced a selective anxiolytic effect in rodent conflict and elevated plus maze paradigms, with a behavioral profile characterized by reduction in anxiety-related behavior without the motor sedation, muscle relaxation, or amnestic effects typical of benzodiazepine anxiolytics at comparably effective doses [1]. This selectivity of effect has been interpreted as evidence that Selank may engage a more circumscribed subset of inhibitory pathways than classical benzodiazepine receptor agonists.
The anxiolytic effect has been reported across multiple behavioral paradigms in rodents, including the elevated plus maze, open field test, and Vogel conflict test. Consistency of directional effect across multiple test paradigms in this species represents the strongest preclinical evidence for Selank's proposed primary activity, though replication by independent groups outside Russia remains limited. Dose-response characterization and the relationship between dose, route, and behavioral effect magnitude are not well established in the accessible literature.
4.2 Serotonergic and Catecholamine Modulation
Narkevich and colleagues examined the effects of Selank on monoamine content in brain regions of rats stratified by baseline anxiety level, reporting that Selank's effects on serotonin and dopamine turnover were partially dependent on the animal's initial anxiety state [5]. In higher-anxiety animals, Selank appeared to normalize elevated monoamine turnover in limbic and striatal regions, while effects in lower-anxiety animals were less pronounced. This state-dependent modulation pattern, if replicable, would be consistent with a modulatory rather than uniformly suppressive effect on monoaminergic systems — a pharmacological profile resembling anxioselective agents rather than broad monoamine depleting or enhancing drugs.
Semenova and colleagues reported that chronic stress produced depletion of catecholamines in stress-relevant brain structures in rats, and that Selank administration partially attenuated these stress-induced changes, normalizing catecholamine levels toward unstressed baseline values [2]. These findings suggest a potential role for Selank in preserving monoaminergic reserve under sustained aversive conditions, though the causal pathway connecting Selank administration to catecholamine preservation has not been established.
4.3 Human Studies — Anxiety and Asthenic Disorders
The most clinically relevant human data on Selank comes from Russian clinical studies examining its use in patients with anxiety and anxiety-asthenic disorders. Uchakina and colleagues published a study reporting that Selank treatment in patients with anxiety-asthenic disorders was associated with reported improvements in anxiety symptom ratings alongside changes in cytokine profiles, including IL-6 alterations, suggesting a combined anxiolytic and immunomodulatory response [3]. This study is notable as one of the few reports of Selank effects in human subjects with a level of methodological detail accessible in the English-language literature.
Russian-language clinical literature describes broader use of Selank in anxiety-related indications, with reported improvements in symptom burden, emotional stability, and cognitive performance under anxiety conditions. These studies are referenced in Russian-language reviews but are not accessible for independent methodological evaluation by English-language researchers, representing a material limitation in assessing the full human evidence base. The absence of randomized, placebo-controlled, double-blind trial data in accessible peer-reviewed publications means that the human evidence for Selank cannot be formally graded above preliminary.
4.4 Immunomodulatory Properties
Building on the tuftsin heritage of the parental sequence, Selank has been investigated for immunomodulatory properties in both animal and human contexts. In the human data reported by Uchakina and colleagues, cytokine profile changes were concurrent with anxiolytic effects, raising the question of whether the immunomodulatory properties of Selank contribute to or modulate its anxiolytic mechanism — for example, through anti-inflammatory effects on CNS microglial function, or through peripheral neuroimmune crosstalk in which cytokine changes influence GABAergic or serotonergic synaptic tone [3].
The immunomodulatory dimension of Selank is a feature not shared by conventional anxiolytics and represents a potential pharmacological differentiator. However, it also complicates mechanistic interpretation: the concurrent anxiolytic and immune-modulatory effects in human studies make it difficult to determine whether reported symptom improvements are attributable to direct CNS anxiolytic activity, to peripheral neuroimmune effects, or to both acting in parallel. Whether immune effects at clinically used doses are beneficial, neutral, or a potential concern in immunologically vulnerable populations has not been adequately studied.
| Study Focus | Model | Route | Primary Finding | Reference |
|---|---|---|---|---|
| Anxiolytic selectivity | Rat elevated plus maze and conflict paradigms | Intraperitoneal | Anxiolytic-like effect without sedation or amnestic properties at effective doses; distinguished from benzodiazepine profile | [1] |
| Catecholamine / stress | Rat chronic stress model | Intraperitoneal | Attenuation of stress-induced catecholamine depletion in limbic brain structures | [2] |
| Immunomodulation (human) | Patients with anxiety-asthenic disorders | Intranasal | Reported changes in cytokine profile including IL-6; concurrent with improvement in anxiety symptom ratings | [3] |
| Tuftsin discovery | Neutrophil / leukocyte assays | Various | Tuftsin (TKPR) identified as endogenous phagocytosis-activating tetrapeptide derived from IgG Fc region; foundational for Selank development | [4] |
| Monoamine levels (brain) | Rat brain regions, stratified by anxiety level | Intraperitoneal | State-dependent modulation of serotonin and dopamine content; normalization effect more pronounced in high-anxiety animals | [5] |
5. Limitations of Current Research
References
- Kozlovskii II, Kozlovskaia MM. "Selective anxiolytic effect of Selank in behavior models in rats and mice." Eksperimental'naya i Klinicheskaya Farmakologiya. 2007;70(2):6–8. [In Russian]
- Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaia MM. "Effect of Selank on the behavior and catecholamine metabolism in rats exposed to chronic stress." Eksperimental'naya i Klinicheskaya Farmakologiya. 2010;73(8):8–11. [In Russian]
- Uchakina ON, Uchakin PN, Miasoedov NF, Ashmarin IP, Shcherbenko VE, Poliakov VO, Shcherbenko OI, Bobkova MV. "Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(5):71–75. [In Russian]
- Najjar VA, Nishioka K. "Tuftsin: a physiological activator of polymorphonuclear leukocyte phagocytic activity." Nature. 1970;228(5272):672–673. doi:10.1038/228672a0
- Narkevich VB, Kudrin VS, Klodt PM, Pokrovskii AA, Kozlovskaia MM, Val'dman AV, Raevskii KS. "Effects of peptide anxiolytic Selank on the content of monoamines and their metabolites in the brain of rats with different levels of anxiousness." Eksperimental'naya i Klinicheskaya Farmakologiya. 2008;71(2):8–11. [In Russian]